Figure 5.

Chondroitin-4-sulfate is reduced in DNIIR cartilage. Sections from wild-type (A), (C), (E) and (G) and dominant-negative transforming growth factor β type II receptor (DNIIR) (B), (D), (F) and (H) tibiae (n = 3 controls and 3 DNIIR) were stained using Alcian blue at critical electrolyte concentration (A) and (B) and immunofluorescence using anti-aggrecan (C) and (D) (green), anti-chondroitin-0-sulfate (E) and (F) (red) and anti-chondroitin-4-sulfate (G) and (H) (red) antibodies. Alcian blue critical electrolyte staining and chondroitin-4-sulfate staining were reduced in DNIIR cartilage, chondroitin-0-sulfate staining was increased and aggrecan staining was comparable to that of controls.

Ramaswamy et al. Arthritis Research & Therapy 2012 14:R49   doi:10.1186/ar3762
Download authors' original image